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ingly Cesaro’s study showed BK viruria occurred at a median
of 18 days (range, 2 to 30), before overt HC, whereas BK
viremia preceded HC by a median of 17 days (range, 0 to 23),
which provides an opportunity for HC prevention.
In conclusion, the study of Laskin et al. demonstrates
a very strong association between BK viremia and risk of HC
in pediatric recipients of HSCT. BK PCR in plasma is a sensi-
tive method to monitor for BK reactivation, and it could be
used in clinical trials to evaluate preemptive treatment for BK
with the primary endpoint of decreasing HC incidence,
similar to the prevention and preemptive guidelines used in
CMV-reactivation management. The ultimate goal of
decreased HC will lead to decreased morbidity and improved
outcomes. This goal also underscores the need for effective
speciﬁc prophylaxis and treatment for BK-associated HC in
our HSCT population. Finally, in light of this study, a larger
multicenter trial is needed with the aim of comparing BK
plasma PCR and BK urine PCR with a universal assay that
detects all 4 genotypes of BK virus.
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Accepted 10 June 2013Human metapneumovirus (hMP) is a relatively recently
described virus (only known since 2001), although studies
of stored blood samples suggest it has been present in
the community going back at least to 1958 [1]. It is a para-
myxovirus, related to respiratory syncytial virus (RSV),
and accounts for between 2% and 7% of community respi-
ratory viral illnesses. As with other community respiratory
viruses, symptoms are frequently nonspeciﬁc at the outset
and include cough, nasal congestion, sore throat, andfever. However, progression to lower respiratory tract
infection can occur. Case series have suggested a high
mortality associated with this infection in transplant
recipients; a report by Englund et al. [2] documented the
association between hMP, respiratory failure, and a septic
shock-like presentation, with death from acute respiratory
failure occurring in 4 of 5 hematopoietic stem cell trans-
plantation (HSCT) recipients. However, despite such reports,
hMP remains an under-recognized cause of infection in
immunocompromised patients.
In this issue an article by Renaud et al. entitled “Mortality
rates of human metapneumovirus and respiratory syncytial
virus lower respiratory tract infections in hematopoietic
stem cell transplant recipients” [3] represents the latest of
many valuable contributions by the group at Fred Hutch-
inson Cancer Research Center to our understanding of
infections after HSCT. Previous work by this group has
elucidated the epidemiology of many different infections
(viral, fungal, bacterial) in this high-risk patient population.
This group’s prior work on respiratory viruses has estab-
lished risk factors and outcomes for these infections and has
R.K. Avery / Biol Blood Marrow Transplant 19 (2013) 1137e1139 1139supported the utility of ribavirin therapy for RSV, although
less strongly for parainﬂuenza virus [4]. The group has also
studied the use of the RSV monoclonal antibody palivizumab
in the HSCT population [5]. They have documented the
challenges involves in performing randomized trials of
therapy for respiratory virus infections in this population, for
example a multicenter study of pre-emptive ribavirin
therapy for RSV upper respiratory tract infection for the
prevention of progression to lower respiratory tract disease
(pneumonia) [6]. Although this study was discontinued due
to slow accrual, valuable lessons were learned, including
a trend toward decreasing viral loads in the ribavirin-treated
group [6]. Most recently, published in this journal earlier this
year, the same group identiﬁed stem cell source and oxygen
requirement as risk factors for poorer outcome in HSCT
recipients with RSV infection [7].
Although RSV infection has been more extensively
studied, hMP infection in this population has been the
subject mainly of case reports and small case series. Thus,
a carefully performed comparative study of risk factors and
outcomes is awelcome addition to the literature. The authors
report that the mortality of RSV and hMP lower respiratory
tract infections in this population was high but notably
exactly the same (43%) with either virus. Their discussions of
different radiographic patterns, which may possibly be
associated with differential outcomes, as well as exploration
of the signiﬁcance of viral load (very high bronchoalveolar
lavage viral loads and detectable viremia were associated
with high mortality) provide new insights into hMP infec-
tion. Risk factors for poor outcome appear to be similar to
those identiﬁed for RSV; in particular, steroid therapy, stem
cell source, oxygen requirement, and mechanical ventilation
were identiﬁed as risk factors for mortality.
The authors attempted to determine whether ribavirin
therapy had any impact on the course of hMP infection. This
analysis was not conclusive, for several reasons. Whereas
aerosolized ribavirin was administered to RSV patients per
institutional protocol, it was given only per clinician choice
in the case of hMP and not as part of a protocol. Immuno-
globulin preparations were also administered to some hMP
patients but not to others. Although multiple in vitro studies
and case reports suggest possible utility of ribavirin and
intravenous immunoglobulin (IVIg) in hMP infection, further
studies are needed to determine optimal therapy. In addi-
tion, the current study does not address the possible utility
of oral ribavirin, which has been reported by other investi-
gators [8]. The current study also does not address the
possible utility of IVIg, although this therapy is commonly
administered with or without ribavirin as in the patients
reported herein.
There are several other questions the current study
cannot answer. Given the high mortality of hMP infection,
rapid pre-emptive therapy would seem to be a logical
intervention to try, yet the initiation of therapy for hMP was
later in time after diagnosis than that for RSV in this study.
This may reﬂect the existence of an institutional protocol and
greater clinician conﬁdence in the utility of therapy for RSV.
Nonetheless, studies involving larger numbers of patients
who were treated earlier after diagnosis of hMP would be of
interest. A randomized controlled trial would be ideal, but
this would likely not be easy to accomplish, as the case of RSV
illustrates. A further question of interest in future studies
would be the risk of infections, including fungal infections, in
the aftermath of hMP infection. The current study reportedcopathogens but did not speciﬁcally study infections occur-
ring later after hMP. Marr and colleagues [9] reported that
respiratory virus infections constitute a risk factor for the
subsequent development of invasive aspergillosis. It will be
of interest to explore this issue further with respect to hMP.
Although many unanswered questions remain, one of the
main implications of the current study is the idea that
clinicians and centers should make sure to include hMP,
particularly by PCR testing, in their diagnostic panels for
respiratory viruses, at least for prognostic reasons if not as
a prelude to initiation of therapy. Finally, the authors make
the point that newer antivirals are needed for treatment of
respiratory viruses, and if and when such agents are devel-
oped, hMP should be among the viruses to be tested
regarding the efﬁcacy of these new agents.
In conclusion, hMP infection appears to be on an equal
footing with RSV in terms of high mortality after HSCT. Risk
factors for poorer outcome were similar between these two
viruses. Therapy with ribavirin and with IVIg preparations
was administered to some patients per clinician choice, but
from the current study it is not possible to establish whether
or not this therapy was helpful, unlike the case of RSV in
which the utility of ribavirin is clearer. Further studies
including larger numbers of patients are needed to answer
the questions of optimal therapy and the utility of pre-
emptive therapy. These investigators are to be commended
for highlighting the importance of hMP virus as a pathogen
and enlarging our understanding of its role in the HSCT
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